The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Open accessAbstract
IMPORTANCE: Cancer is caused by a diverse array of somatic and germline genomic aberrations. Advances in genomic sequencing technologies have improved the ability to detect these molecular aberrations with greater sensitivity. However, integrating them into clinical management in an individualized manner has proven challenging. OBJECTIVE: To evaluate the use of integrative clinical sequencing and genetic counseling in the assessment and treatment of children and young adults with cancer. DESIGN, SETTING, AND PARTICIPANTS: Single-site, observational, consecutive case series (May 2012-October 2014) involving 102 children and young adults (mean age, 10.6 years; median age, 11.5 years, range, 0-22 years) with relapsed, refractory, or rare cancer. EXPOSURES: Participants underwent integrative clinical exome (tumor and germline DNA) and transcriptome (tumor RNA) sequencing and genetic counseling. Results were discussed by a precision medicine tumor board, which made recommendations to families and their physicians. MAIN OUTCOMES AND MEASURES: Proportion of patients with potentially actionable findings, results of clinical actions based on integrative clinical sequencing, and estimated proportion of patients or their families at risk of future cancer. RESULTS: Of the 104 screened patients, 102 enrolled with 91 (89%) having adequate tumor tissue to complete sequencing. Only the 91 patients were included in all calculations, including 28 (31%) with hematological malignancies and 63 (69%) with solid tumors. Forty-two patients (46%) had actionable findings that changed their cancer management: 15 of 28 (54%) with hematological malignancies and 27 of 63 (43%) with solid tumors. Individualized actions were taken in 23 of the 91 (25%) based on actionable integrative clinical sequencing findings, including change in treatment for 14 patients (15%) and genetic counseling for future risk for 9 patients (10%). Nine of 91 (10%) of the personalized clinical interventions resulted in ongoing partial clinical remission of 8 to 16 months or helped sustain complete clinical remission of 6 to 21 months. All 9 patients and families with actionable incidental genetic findings agreed to genetic counseling and screening. CONCLUSIONS AND RELEVANCE: In this single-center case series involving young patients with relapsed or refractory cancer, incorporation of integrative clinical sequencing data into clinical management was feasible, revealed potentially actionable findings in 46% of patients, and was associated with change in treatment and family genetic counseling for a small proportion of patients. The lack of a control group limited assessing whether better clinical outcomes resulted from this approach than outcomes that would have occurred with standard care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., McGuire, A. L., Nussbaum, R. L., O’Daniel, J. M., Ormond, K. E., et al. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.73 · Cited by 2,541
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Medulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,339
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Self-citationAdvances in understanding cancer genomes through second-generation sequencing
Meyerson, M., Gabriel, S., & Getz, G. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2841 · Cited by 1,116
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
Pui, C.-H., Carroll, W. L., Meshinchi, S., & Arceci, R. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7405 · Cited by 842
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Self-citationSorensen, P. H. B., Lynch, J. C., Qualman, S. J., Tirabosco, R., Lim, J. F., Maurer, H. M., Bridge, J. A., Crist, W. M., Triche, T. J., & Barr, F. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.137 · Cited by 742
The Genetic Landscape of the Childhood Cancer Medulloblastoma
Parsons, D. W., Li, M., Zhang, X., Jones, S., Leary, R. J., Lin, J. C.-H., Boca, S. M., Carter, H., Samayoa, J., Bettegowda, C., et al. (2011) · Science · doi:10.1126/science.1198056 · Cited by 717
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Kalyana-Sundaram, S., Sam, L., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 628
Self-citationRearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia
Mullighan, C. G., Collins-Underwood, J. R., Phillips, L. A. A., Loudin, M. G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R. C., Willman, C. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.469 · Cited by 623
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
A novel retinoblastoma therapy from genomic and epigenetic analyses
Zhang, J., Benavente, C. A., McEvoy, J., Flores-Otero, J., Ding, L., Chen, X., Ulyanov, A., Wu, G., Wilson, M., Wang, J., et al. (2012) · Nature · doi:10.1038/nature10733 · Cited by 516
Oberlin, O., Rey, A., Lyden, E., Bisogno, G., Stevens, M. C. G., Meyer, W. H., Carli, M., & Anderson, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7207 · Cited by 484
Bourgeois, J. M., Knezevich, S. R., Mathers, J. A., & Sorensen, P. H. B. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200007000-00005 · Cited by 338
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
Carbone, M., Ferris, L. K., Baumann, F., Napolitano, A., Lum, C. A., Flores, E. G., Gaudino, G., Powers, A., Bryant-Greenwood, P., Krausz, T., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-179 · Cited by 323
London, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3392 · Cited by 318
Gaynon, P. S., Angiolillo, A. L., Carroll, W. L., Nachman, J. B., Trigg, M. E., Sather, H. N., Hunger, S. P., Devidas, M., & for the Children's Oncology Group, A. C. (2010) · Leukemia · doi:10.1038/leu.2009.262 · Cited by 293
Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene
Welch, J. S. (2011) · JAMA · doi:10.1001/jama.2011.497 · Cited by 252
Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma
Mosquera, J. M., Sboner, A., Zhang, L., Kitabayashi, N., Chen, C., Sung, Y. S., Wexler, L. H., LaQuaglia, M. P., Edelman, M., Sreekantaiah, C., et al. (2013) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22050 · Cited by 233
Sumegi, J., Streblow, R., Frayer, R. W., Cin, P. D., Rosenberg, A., Meloni‐Ehrig, A., & Bridge, J. A. (2010) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20731 · Cited by 169
Widemann, B. C., Kim, A., Fox, E., Baruchel, S., Adamson, P. C., Ingle, A. M., Bender, J. G., Burke, M., Weigel, B. J., Stempak, D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3284 · Cited by 114
Fernandez, C. V., Gao, J., Strahlendorf, C., Moghrabi, A., Pentz, R. D., Barfield, R. C., Baker, J. N., Santor, D. A., Weijer, C., & Kodish, E. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5223 · Cited by 94
Tabor, H. K., Brazg, T., Crouch, J. M., Namey, E., Fullerton, S. M., Beskow, L. M., & Wilfond, B. S. (2011) · Journal of Empirical Research on Human Research Ethics · doi:10.1525/jer.2011.6.4.41 · Cited by 61
Haga, S. B., O’Daniel, J. M., Tindall, G. M., Lipkus, I., & Agans, R. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821afcc0 · Cited by 53
Future of Clinical Genomics in Pediatric Oncology
Janeway, K. A., Place, A. E., Kieran, M. W., & Harris, M. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8470 · Cited by 48
Incidental Findings in Pediatric Research
Wilfond, B. S., & Carpenter, K. J. (2008) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2008.00277.x · Cited by 45
Goltsov, A., Langdon, S. P., Goltsov, G., Harrison, D. J., & Bown, J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00013 · Cited by 17
Genetically InFormed Therapies—A “GIFT” for Children with Cancer
Thiele, C. J., & Cohn, S. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1940 · Cited by 7
Cited by
The Landscape of Circular RNA in Cancer
Vo, J. N., Cieslik, M., Zhang, Y., Shukla, S., Xiao, L., Zhang, Y., Wu, Y.-M., Dhanasekaran, S. M., Engelke, C. G., Cao, X., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.021 · Cited by 1,738
Self-citationIntegrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863
Self-citationTranslating RNA sequencing into clinical diagnostics: opportunities and challenges
Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D., & Craig, D. W. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.10 · Cited by 809
Garcia, E. P., Minkovsky, A., Jia, Y., Ducar, M. D., Shivdasani, P., Gong, X., Ligon, A. H., Sholl, L. M., Kuo, F. C., MacConaill, L. E., et al. (2017) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2016-0527-oa · Cited by 524
Mandelker, D., Zhang, L., Kemel, Y., Stadler, Z. K., Joseph, V., Zehir, A., Pradhan, N., Arnold, A., Walsh, M. F., Li, Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.11137 · Cited by 511
Metadata
- Authors
- Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., Frank, K. M., Prensner, J. R., Asangani, I., Palanisamy, N., Dillman, J. R., Rabah, R. M., Kunju, L. P., Everett, J., Raymond, V. M., Ning, Y., Su, F., Wang, R., Stoffel, E. M., Innis, J. W., Roberts, J. S., Robertson, P. L., Yanik, G., Chamdin, A., Connelly, J. A., Choi, S., Harris, A. C., Kitko, C., Rao, R. J., Levine, J. E., Castle, V. P., Hutchinson, R. J., Talpaz, M., Robinson, D. R., & Chinnaiyan, A. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-09-01
- Volume
- 314
- Issue
- 9
- Pages
- 913
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1911918948
- Cited by
- 411
- References
- 34
- FWCI
- 14.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.